Efficacy and Safety Study of Bimatoprost Sustained-Release (SR) in Participants With Open-angle Glaucoma or Ocular Hypertension

Study Overview
=================
Brief Summary
-----------------
This study will evaluate the efficacy and safety of bimatoprost SR in participants with open-angle glaucoma or ocular hypertension. The study includes a 12-month treatment period with an 8-month extended follow-up.

Official Title
-----------------
The Efficacy and Safety of Bimatoprost SR in Patients With Open-angle Glaucoma or Ocular Hypertension

Conditions
-----------------
Glaucoma, Open-Angle, Ocular Hypertension

Intervention / Treatment
-----------------
* Drug: Bimatoprost SR
* Drug: Active Comparator: Timolol 0.5%
* Other: Sham: Applicator Without Needle
* Drug: Timolol Vehicle (placebo)


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: -Diagnosis of either open-angle glaucoma or ocular hypertension in each eye and both eyes require IOP-lowering treatment. Exclusion Criteria: Previous enrollment in another Allergan Bimatoprost SR Study. Eye surgery (including cataract surgery) and/or any eye laser surgery within the past 6 months in the study eye Anticipated need for laser eye surgery in either eye within the first 52 weeks of the study duration History of glaucoma surgery

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Bimatoprost SR 15 μg<br>Study Eye: bimatoprost sustained release (SR) 15 μg administered on Day 1 (Period 1), Week 16 (Period 2), and Week 32 (Period 3); timolol vehicle administered once in the morning and once in the evening for up to 20 months. Non-Study Eye: sham administration on Day 1 (Period 1), Week 16 (Period 2), and Week 32 (Period 3); timolol 0.5% administered once in the morning and once in the evening for up to 20 months. | Drug: Bimatoprost SR<br>* Bimatoprost SR administered in the study eye on Day 1, Week 16, and Week 32.<br>* Other names: AGN-192024;Drug: Active Comparator: Timolol 0.5%<br>* Timolol 0.5% administered once in the morning and once in the evening for up to 20 months.<br>Other: Sham: Applicator Without Needle<br>* Sham administered on Day 1, Week 16, and Week 32.<br>Drug: Timolol Vehicle (placebo)<br>* Timolol vehicle administered once in the morning and once in the evening for up to 20 months.<br>|
| Experimental: Bimatoprost SR 10 μg<br>Study Eye: bimatoprost SR 10 μg administered on Day 1 (Period 1), Week 16 (Period 2), and Week 32 (Period 3); timolol vehicle administered once in the morning and once in the evening for up to 20 months. Non-Study Eye: sham administration on Day 1 (Period 1), Week 16 (Period 2), and Week 32 (Period 3); timolol 0.5% administered once in the morning and once in the evening for up to 20 months. | Drug: Bimatoprost SR<br>* Bimatoprost SR administered in the study eye on Day 1, Week 16, and Week 32.<br>* Other names: AGN-192024;Drug: Active Comparator: Timolol 0.5%<br>* Timolol 0.5% administered once in the morning and once in the evening for up to 20 months.<br>Other: Sham: Applicator Without Needle<br>* Sham administered on Day 1, Week 16, and Week 32.<br>Drug: Timolol Vehicle (placebo)<br>* Timolol vehicle administered once in the morning and once in the evening for up to 20 months.<br>|
| Active Comparator: Timolol 0.5%<br>Study Eye and Non-Study Eye: sham administered on Day 1 (Period 1), Week 16 (Period 2), and Week 32 (Period 3); timolol 0.5% administered once in the morning and once in the evening for up to 20 months. | Drug: Active Comparator: Timolol 0.5%<br>* Timolol 0.5% administered once in the morning and once in the evening for up to 20 months.<br>Other: Sham: Applicator Without Needle<br>* Sham administered on Day 1, Week 16, and Week 32.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change From Baseline in IOP in the Study Eye at Week 12 (Hours 0 and 2) | IOP is a measurement of the fluid pressure inside the study eye. Measurements were taken at Hours 0 and 2. The study eye is defined as the eye that meets the entry criteria. If both eyes meet the entry criteria, the eye with the higher IOP at Baseline Hour 0 will be selected as the study eye. If both eyes had the same IOP at Hour 0, then the right eye was designated as the study eye. A mixed-effects model with repeated measures (MMRM) was used for analyses. A negative change from baseline indicates an improvement and a positive change from baseline indicates a worsening. | Baseline (Hours 0 and 2) to Week 12 (Hours 0 and 2) | 
| IOP in the Study Eye at Week 2 (Hour 0) | IOP is a measurement of the fluid pressure inside the study eye. Measurements were taken at Hours 0 and 2. The study eye is defined as the eye that meets the entry criteria. If both eyes meet the entry criteria, the eye with the higher IOP at Baseline Hour 0 will be selected as the study eye. If both eyes had the same IOP at Hour 0, then the right eye was designated as the study eye. MMRM was used for analyses. | Week 2 (Hour 0) | 
| IOP in the Study Eye at Week 2 (Hour 2) | IOP is a measurement of the fluid pressure inside the study eye. Measurements were taken at Hours 0 and 2. The study eye is defined as the eye that meets the entry criteria. If both eyes meet the entry criteria, the eye with the higher IOP at Baseline Hour 0 will be selected as the study eye. If both eyes had the same IOP at Hour 0, then the right eye was designated as the study eye. MMRM was used for analyses. | Week 2 (Hour 2) | 
| IOP in the Study Eye at Week 6 (Hour 0) | IOP is a measurement of the fluid pressure inside the study eye. Measurements were taken at Hours 0 and 2. The study eye is defined as the eye that meets the entry criteria. If both eyes meet the entry criteria, the eye with the higher IOP at Baseline Hour 0 will be selected as the study eye. If both eyes had the same IOP at Hour 0, then the right eye was designated as the study eye. MMRM was used for analyses. | Week 6 (Hour 0) | 
| IOP in the Study Eye at Week 6 (Hour 2) | IOP is a measurement of the fluid pressure inside the study eye. Measurements were taken at Hours 0 and 2. The study eye is defined as the eye that meets the entry criteria. If both eyes meet the entry criteria, the eye with the higher IOP at Baseline Hour 0 will be selected as the study eye. If both eyes had the same IOP at Hour 0, then the right eye was designated as the study eye. MMRM was used for analyses. | Week 6 (Hour 2) | 
| IOP in the Study Eye at Week 12 (Hour 0) | IOP is a measurement of the fluid pressure inside the study eye. Measurements were taken at Hours 0 and 2. The study eye is defined as the eye that meets the entry criteria. If both eyes meet the entry criteria, the eye with the higher IOP at Baseline Hour 0 will be selected as the study eye. If both eyes had the same IOP at Hour 0, then the right eye was designated as the study eye. MMRM was used for analyses. | Week 12 (Hour 0) | 
| IOP in the Study Eye at Week 12 (Hour 2) | IOP is a measurement of the fluid pressure inside the study eye. Measurements were taken at Hours 0 and 2. The study eye is defined as the eye that meets the entry criteria. If both eyes meet the entry criteria, the eye with the higher IOP at Baseline Hour 0 will be selected as the study eye. If both eyes had the same IOP at Hour 0, then the right eye was designated as the study eye. MMRM was used for analyses. | Week 12 (Hour 2) | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change From Baseline in IOP in the Study Eye | IOP is a measurement of the fluid pressure inside the study eye. Measurements were taken at Hours 0 and 2. The study eye is defined as the eye that meets the entry criteria. If both eyes meet the entry criteria, the eye with the higher IOP at Baseline Hour 0 will be selected as the study eye. If both eyes had the same IOP at Hour 0, then the right eye was designated as the study eye. MMRM was used for analyses. A negative change from baseline indicates an improvement and a positive change from baseline indicates a worsening. | Baseline (Hours 0 and 2) to Weeks 2 and 6 (Hours 0 and 2) |